How many doses are in a pack of Slynd (drospirenone), a progestin-only pill?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Drospirenone and Ethinyl Estradiol Tablets, USP 3 mg/0. 02 mg are available as follows: NDC 68462-720-29 1 carton containing 3 individual pouches. Each pouch contains 1 blister of 28 tablets. The FDA drug label for Slynd (drospirenone) indicates that each pouch contains 1 blister of 28 tablets. Therefore, the number of doses in a pack is 28 tablets per blister, and since there are 3 individual pouches in a carton, the total number of doses in a pack is 3 x 28 = 84 tablets 1.

From the Research

Slynd birth control packs typically contain 28 tablets per pack, with 24 active tablets and 4 inactive tablets, as indicated by the most recent and highest quality studies available 2. The active tablets in Slynd contain a progestin-only hormone, which is taken daily for 24 consecutive days, followed by the 4 inactive tablets to complete the 28-day cycle. This progestin-only pill (POP) differs from traditional combination birth control pills as it contains no estrogen. Some key points to consider when using Slynd include:

  • The importance of taking the pill at the same time each day to maintain consistent hormone levels for effective contraception
  • The 24-hour missed pill window, which provides slightly more flexibility compared to traditional mini-pills that must be taken within a stricter timeframe
  • The potential for variable bleeding patterns, which can be a common complaint among women using progestin-only pills, as noted in studies such as 3 and 4
  • The benefits of using a progestin-only pill, including the reduced risk of venous thromboembolism and the ability to use the pill while breastfeeding, as discussed in studies such as 5 and 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.